Group 1: Company Overview - Chengdu Sailano Medical Technology Co., Ltd. (Sailano) has officially signed to establish its headquarters in Chengdu Tianfu International Bio-City, focusing on the field of structural heart disease [1][3] - Sailano aims to become a unicorn in the field of pan-cardiac disease medical devices, with a global innovation capability and a forward-looking vision [3] - The company holds 21 invention patents and 19 utility model patents, showcasing its strong intellectual property portfolio [3] Group 2: Research and Development - Sailano plans to build a headquarters, R&D center, and production base in the bio-city to systematically conduct research, production, and sales of medical devices for structural heart disease [3] - The company has established close clinical trial cooperation with top cardiac centers in China, creating a collaborative innovation system from clinical needs to technology transfer [3] - Sailano's product pipeline targets the core area of interventional treatment for structural heart disease, with several in-development products possessing "international advanced" technical advantages [3] Group 3: Clinical Applications and Collaborations - The company will leverage its existing clinical cooperation network and R&D platform to accelerate clinical research, registration, and industrialization of core products after settling in the bio-city [3] - The high-frequency skin ultrasound technology developed by Tianfu Jin Cheng Laboratory has entered clinical validation, providing a new tool for skin disease diagnosis and treatment evaluation [6][10] - The technology aims to enhance the precision of skin disease diagnosis by offering non-invasive, real-time imaging capabilities [10] Group 4: Industry Developments - Chengdu Biomedicine has seen multiple advancements in various subfields, including the structural heart disease sector [4] - Chengdu Baili Tianheng Pharmaceutical Co., Ltd. has been recognized in the "2025 Hurun China 500" list, ranking 86th with a value of 153 billion yuan, an increase of 79.5 billion yuan [12] - Baili Tianheng is developing innovative drugs in the tumor macromolecule treatment field and has received multiple breakthrough therapy designations from regulatory agencies [12]

转自：成都日报锦观 天府中药城进军医疗器械产业新领域 本报讯 （成都日报锦观新闻记者 袁弘） 记者昨日获悉，彭州经开区企业艾立本科技完成A+轮融资， 加速提高全国产超高效液相色谱三重四极杆质谱联用仪市占率。这也成为2026年彭州经开区抢滩万亿医 疗器械新版图的"首作"。 作为四川省专精特新企业、国家级高新技术企业，艾立本科技此次完成的数千万元人民币A+轮融资， 由四川产业基金川创投交子梧桐基金领投，老股东四川发展彭州全球生物医药基金跟投。本轮融资资金 将主要用于艾立本自主正向研制的超高效液相色谱三重四极杆质谱联用仪的产能提升、市场推广及产品 升级等方面工作。 "面对全国园区在生命科学领域的同质化竞争，单纯的规模扩张已经难以持续，彭州经开区正将深厚的 中医药产业底蕴转化为在高端医疗器械赛道上的独特竞争力。彭州经开区相关负责人表示，通过构 建"研发—制造—应用"闭环，深化"药+械+数"融合发展，园区目前已经形成了以"中医诊疗设备、中药 源性医疗器械、智慧健康服务"为特色的产业生态，走出了一条兼具中药基因、彭州特色的医疗器械产 业发展之路。 ...

Core Viewpoint - Ailibin Technology has successfully completed a multi-million RMB A+ round financing, which will primarily be used for enhancing the production capacity, market promotion, and product upgrades of its self-developed ultra-high-performance liquid chromatography triple quadrupole mass spectrometer [1][2]. Financing Details - The financing round was led by Sichuan Industrial Fund Chuan Chuang Investment and the Jiaozi Wutong Fund, with participation from existing shareholder Sichuan Development Pengzhou Global Biomedical Fund [2]. Product Development - The funds raised will focus on the production enhancement, market promotion, and product upgrades of Ailibin's ultra-high-performance liquid chromatography triple quadrupole mass spectrometer [1][2]. - Ailibin has also invited users from various industries to apply for free trials of the prototype [2].